The first‐in‐man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT‐HF trial

Aims The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na+ overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2017-04, Vol.19 (4), p.566-575
Main Authors: Bundgaard, Henning, Axelsson, Anna, Hartvig Thomsen, Jakob, Sørgaard, Mathias, Kofoed, Klaus F., Hasselbalch, Rasmus, Fry, Natasha A.S., Valeur, Nana, Boesgaard, Søren, Gustafsson, Finn, Køber, Lars, Iversen, Kasper, Rasmussen, Helge H.
Format: Article
Language:English
Subjects:
Acetanilides - therapeutic use
Adrenergic beta-3 Receptor Agonists - therapeutic use
Adrenergic receptors
Adult
Aged
Cardiac contractility
Double-Blind Method
Female
Heart failure
Heart Failure - diagnostic imaging
Heart Failure - drug therapy
Heart Failure - physiopathology
Humans
Male
Membrane sodium–potassium pump
Middle Aged
Neurohormonal activation
Oxidant stress
Stroke Volume
Thiazoles - therapeutic use
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na+ overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF. Methods and results In a double‐blind trial we randomly assigned 70 patients with NYHA class II–III HF and LVEF
ISSN:1388-9842
1879-0844
DOI:10.1002/ejhf.714